Liver Failure Clinical Trial
Official title:
Terlipressin Administration in Patients Undergoing Major Liver Resection: a Prospective Randomized Blinded Trial
This study investigates if the administration of terlipressin reduces complications after major liver surgery.
Background
Surgery offers the only potential cure in many patients with primary or metastatic liver
cancer. Extending the limits and improving safety of liver resection would allow more
patients to benefit from surgery and to increase their survival. The prerequisite for
successful and safe liver surgery is the optimal regeneration of the remaining hepatic tissue
in order to fulfill the metabolic demands of the patient. Liver regeneration depends on a
correct portal pressure and portal blood flow. In the preliminary results the investigators
show an elevation of portal pressure post partial hepatectomy in mice. Pharmacologic
reduction of such elevated portal pressure using terlipressin, a vasopressin agonist, was
associated with improved liver regeneration.
Objective
Surgery offers the only potential cure in many patients with primary or metastatic liver
cancer. Extending the limits and improving safety of liver resection would allow more
patients to benefit from surgery and to increase their survival. Liver regeneration depends
on a correct portal pressure and portal blood flow. Pharmacologic reduction of elevated
portal pressure using terlipressin, a vasopressin agonist, is potentially associated with
improved liver regeneration. Aim: To perform a prospective randomized trial comparing
terlipressin versus placebo in patients undergoing major hepatic resection.
Methods
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03791190 -
RCA for CRRT in Liver Failure and High Risk Bleeding Patients
|
N/A | |
Recruiting |
NCT05989958 -
The Safety and Tolerability Study of HepaCure in Chinese Subjects With Acute-On-Chronic Liver Failure
|
Phase 1 | |
Completed |
NCT02557724 -
Mobilization of Mesenchymal Stem Cells During Liver Transplantation
|
||
Recruiting |
NCT01698723 -
A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus
|
Phase 2 | |
Completed |
NCT01425385 -
Autoregulation Assessment During Liver Transplantation
|
N/A | |
Completed |
NCT01404793 -
SPME For Metabolomics And Concomitant Measurements Of Rocuronium Bromide Levels In Liver Transplantation
|
N/A | |
Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
Completed |
NCT03864497 -
Myocardial Perfusion Imaging in Liver Transplantation Candidates
|
||
Completed |
NCT00287235 -
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
|
N/A | |
Completed |
NCT03650920 -
Hepatitis C Virus (HCV) Positive Liver Grafts in HCV Negative Recipients
|
N/A | |
Recruiting |
NCT05517668 -
Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose
|
Phase 2 | |
Recruiting |
NCT05726032 -
Empagliflozin in Patients With Cirrhosis and Ascites
|
Phase 2 | |
Recruiting |
NCT04548596 -
NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
|
||
Recruiting |
NCT02331745 -
RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure
|
Phase 4 | |
Not yet recruiting |
NCT01961440 -
Prognosis Scoring System for Acute-on-Chronic Liver Failure
|
N/A | |
Active, not recruiting |
NCT01221454 -
Allogenic Bone Marrow Stem Cell Transplantation in Liver Failure
|
Phase 2 | |
Completed |
NCT00772148 -
Pharmacokinetics of LCP-Tacroâ„¢ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients
|
Phase 2 | |
Completed |
NCT05592106 -
Gd-EOB-DTPA-enhanced T1 Map for Predicting Postoperative Liver Failure
|
||
Not yet recruiting |
NCT06014320 -
Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
|
||
Recruiting |
NCT04221672 -
The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy
|
Phase 3 |